By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom - 2From Certificate to Dollars: College Majors with Extraordinary Monetary Prizes
- 36 Methods for further developing Rest Quality
- 4We may have less control over how long we live than previously thought
- 5They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- Which Switch Game Do You Suggest? Share Your Decision
- RFK Jr.'s handpicked vaccine panel just voted to stop recommending hepatitis B shots for all newborns. Why experts object.
- NASA's make-or-break moon shot
- Europe could get 42 more days of summer by the year 2100 due to climate change
- Popular Film Areas: A Worldwide Manual for Film Enchantment
- Scientists are getting our robotic explorers ready to help send humans to Mars
- A soft launch, an unfollow and a lot of questions: Breaking down the 'Summer House' romance blowing up group chats
- 9 Under-The-Radar Malaysian Islands To Consider Instead Of Thailand Or Indonesia
